The natural history of recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC) is highly variable. Prognoses of patients with R/M-NPC are influenced by factors such as disease burden (oligometastatic [<3-5 lesions] vs polymetastatic), sites of involvement (lung and lymph nodes vs other visceral and skeletal involvement), and timing of distant metastatic recurrences (de novo vs metachronous). For patients who are fit for systemic therapy, gemcitabine-cisplatin (GP) doublet therapy is the current chemotherapy recommendation, achieving a progression-free survival (PFS) of 7.9 months and overall survival (OS) of 22.1 months.1 More recently, 2 large randomized clinical phase 3 trials—CAPTAIN-1st2 and JUPITER-023—reported that the addition of anti–programmed cell death-1 (anti-PD-1) antibodies (camrelizumab2 and toripalimab3) in combination with GP, followed by maintenance anti-PD-1 antibody treatment until disease progression or up to 2 years, was superior to GP alone (median PFS for combination therapy, 10.8 months2 and 11.7 months3).
Ng W, Chua MLK, Lee AWM. Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma—Magic Bullet or Pandora’s Box? JAMA Oncol. 2022;8(4):524–525. doi:10.1001/jamaoncol.2021.7365
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.